DURAVYU Falls Short on Primary Endpoint in LUGANO, Yet Secondary Results Offer a Silver Lining
EYPT is trading near its 52-week low of $9.65 (54% below the low).
Summary
DURAVYU missed the primary endpoint in the LUGANO Phase 3 trial for wet AMD, but showed strong secondary results including a 42% reduction in treatment burden. The company will rely on the LUCIA trial results in Q4 2026 to support an NDA filing.
Updates
· Dow Jones Newswires — Shares fell 71% to $4.30, the worst single-day drop on record. Citi cut DURAVYU's probability of success to 40% from 60% but maintained Buy.
Key Events · Product Development and Regulatory · EYPT
-
Primary Endpoint Missed
DURAVYU failed to achieve non-inferiority in mean change in BCVA versus aflibercept in the full LUGANO dataset, confounded by a 9-patient asymmetric cohort with vision loss unrelated to wet AMD.
-
Ad Hoc Analysis Shows Non-Inferiority
Excluding the 9-patient asymmetric cohort, DURAVYU achieved non-inferiority with a nominal p-value of 0.0096, with a mean change in BCVA of +5.9 letters versus +3.5 for aflibercept.
-
Strong Secondary Endpoints
DURAVYU demonstrated a 42% reduction in treatment burden (p<0.0001), 76% supplement-free rate up to Week 32, and 54% supplement-free up to Week 56, with only a 4-micron difference in central subfield thickness.
-
Favorable Safety Profile
No cases of insert migration, retinal vasculitis, or severe intraocular inflammation; low discontinuation rate of 6% through Week 56 in each arm.
Analysis · EYPT · Industrial Applications And Services
The lead drug candidate DURAVYU did not meet the primary endpoint of non-inferiority in visual acuity versus aflibercept in the full LUGANO Phase 3 trial dataset. However, an ad hoc analysis that excluded 9 patients with vision loss unrelated to wet AMD achieved non-inferiority, and compelling secondary endpoints included a 42% reduction in treatment burden and a favorable safety profile. These mixed results create significant uncertainty for the drug's regulatory path, with the next pivotal readout from the LUCIA trial expected in Q4 2026. The stock is trading near its 52-week low, reflecting the market's negative reaction to the primary endpoint miss.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 44.9% of the 303 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EYPT was trading at $4.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.65 to $19.11. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.